A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCL, UCLH and the Francis Crick Institute.
University College LondonJul 18 2024 A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCL, UCLH and the Francis Crick Institute.
Since the beginning of the COVID-19 pandemic, the proportion of SARS-CoV-2 infections that result in death has fallen from a high of almost 1,400 deaths on 19 January 2021 to 143 deaths on 21 June 2024. This is partly down to increased immunity from prior infection or vaccination, as well as improved treatments for those who become seriously ill such as dexamethasone, a steroid that helps to tackle the hyper-inflammation that was a key factor in many COVID-19 deaths.
Patients treated with dornase alfa had a 33% reduction in systemic inflammation on top of the reduction provided by dexamethasone, as measured by C-reactive protein levels in the blood over seven days or until they were discharged from hospital. The next step will be to conduct larger clinical trials to ensure dornase alfa is safe and effective for treating severe COVID-19 pneumonia. There is also potential for the drug to be trialled for other respiratory infections and conditions, such as acute exacerbations of pulmonary fibrosis, where inflammation of already scarred lung tissue affects how well oxygen can be absorbed.
Pneumonia Clinical Trial C-Reactive Protein Cystic Fibrosis Dexamethasone Fibrosis Hospital Immune System Inflammation Influenza Medicine Oxygen Pandemic Protein Pulmonary Fibrosis Respiratory SARS SARS-Cov-2
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Clinical trial: Repurposed drug improves outcomes for patients with severe COVID-19 pneumoniaA drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCL, UCLH and the Francis Crick Institute.
Weiterlesen »
Life changing cystic fibrosis drugs approved for NHS patientsThe decision to green light three treatments - Kaftrio, Symkevi and Orkambi - follows years of campaigning by the Cystic Fibrosis Trust and patients
Weiterlesen »
Hopes high for vital cystic fibrosis medicines in NI as talks 'near conclusion'Health officials remain locked in 'commercial' talks with a US pharmaceutical giant on supply of breakthrough cystic fibrosis medicines
Weiterlesen »
Cystic fibrosis patient faces Creon drug supply battleHannah Richards needs Creon so she can take a life-changing drug but supplies may be low until 2026.
Weiterlesen »
Prime editing efficiently corrects cystic fibrosis mutation in human lung cells, study showsCystic fibrosis is one of the most common genetic disorders, causing thick mucus build-up in the lungs and other parts of the body, breathing problems, and infection.
Weiterlesen »
Cystic fibrosis: School-aged children found to benefit from triple combination therapyCystic fibrosis is a hereditary disease that so far has been incurable. Those affected have thick, viscous mucus secretions in their lungs, and lung function diminishes steadily over time. Today, triple combination therapy makes it possible to address the root causes of the defect underlying the disease.
Weiterlesen »